《慢性阻塞性肺疾病全球创议》2025更新评论:聚焦个体化治疗、并发症管理及疫苗接种  

Review of the 2025 Global Initiative for Chronic Obstructive Lung Disease(GOLD)updates:focusing on personalized treatment,comorbidity management,and vaccination

作　　者：蒋琦 马义铭 陈燕[1] Jiang Qi;Ma Yiming;Chen Yan(Department of Respiratory and Critical Care Medicine,The Second Xiangya Hospital,Central South University,Changsha 410011,China)

机构地区：[1]中南大学湘雅二医院呼吸与危重症医学科,长沙410011

出　　处：《结核与肺部疾病杂志》2025年第2期125-127,共3页Journal of Tuberculosis and Lung Disease

基　　金：国家自然科学基金(82370054,82070049)。

摘　　要：慢性阻塞性肺疾病(简称“慢阻肺病”)是一种常见的、可预防和治疗的慢性气道疾病,特征为持续性气流受限和呼吸系统症状。由于慢阻肺病显著的异质性,精准的个体化治疗显得尤为重要。《慢性阻塞性肺疾病全球创议》2025(简称“GOLD 2025”)的更新,通过整合最新循证医学成果,为慢阻肺病的管理带来了重要里程碑。作者重点对GOLD 2025中个体化治疗、并发症管理及疫苗接种进行评述,旨在为临床慢阻肺病工作者优化治疗和预防策略提供一定的参考及启示,以期提升患者生活质量并改善长期预后。Chronic obstructive pulmonary disease(COPD)is a common,preventable,and treatable chronic airway disease characterized by persistent airflow limitation and respiratory symptoms.Given its significant heterogeneity,precise individualized treatment is of paramount importance.The 2025 update of the Global Initiative for Chronic Obstructive Lung Disease(GOLD)represents a major milestone in COPD management by integrating the latest evidence-based findings and refining therapeutic strategies.The authors focuse on key updates in GOLD 2025,including personalized treatment,comorbidity management,and vaccination strategies.It aims to provide clinical COPD practitioners with insights and guidance to optimize treatment and prevention strategies,ultimately improving patients’quality of life and long-term outcomes.

关 键 词：肺疾病 慢性阻塞性 治疗 疾病管理 评论 

分 类 号：R563.9[医药卫生—呼吸系统]